Veru Inc. reported a net loss of $5.3 million, or $0.26 per share, for the fiscal 2026 first quarter, a notable improvement from the $8.9 million net loss in the prior year. The company also saw a substantial increase in cash, cash equivalents, and restricted cash, reaching $33.0 million.

Veru Inc. announced its fiscal year 2025 financial results, with a net loss of $22.7 million, or $1.55 per share. The company reported positive efficacy and safety results from its Phase 2b QUALITY study for enobosarm in combination with GLP-1 RA, receiving FDA regulatory clarity. Veru plans to initiate the Phase 2b PLATEAU clinical study in Q1 calendar year 2026.

Veru Inc. reported a significant decrease in net loss and operating loss for the fiscal third quarter of 2025 compared to the same period last year, driven by reduced research and development and selling, general, and administrative expenses. The company also announced positive clinical trial results for enobosarm, its lead drug candidate for chronic weight loss management.

Veru Inc. reported a net loss of $7.9 million for the fiscal second quarter of 2025, an improvement from the $10.0 million net loss in the same period last year. The company saw a decrease in operating loss from continuing operations and an increase in research and development expenses, while selling, general, and administrative expenses decreased.

Veru reported a net loss of $8.9 million, or $0.06 per share, for the first quarter of fiscal 2025. The company sold its FC2 Female Condom business for $18 million and announced positive Phase 2b QUALITY study topline results for enobosarm + semaglutide.

Veru Inc. reported an increase in net revenues to $4.0 million and a decrease in net loss to $11.0 million for the third quarter of fiscal year 2024. The company also achieved full enrollment in its Phase 2b QUALITY clinical trial for Enobosarm.

Veru Inc. reported a decrease in net revenues to $4.1 million from $6.6 million, a decrease in gross profit to $0.7 million from $4.1 million, and a decrease in operating loss to $9.9 million versus $34.4 million compared to the same quarter last year. Net loss was $10.0 million, or $0.07 per share, compared to $33.8 million, or $0.42 per share, as restated.

Veru Inc. reported a decrease in net revenues to $2.1 million from $2.5 million, and an increase in gross profit to $1.2 million from $0.7 million compared to the previous year. The company's cash and cash equivalents totaled $40.6 million. The FDA cleared the IND application for enobosarm in combination with GLP-1 drugs, and the Phase 2b obesity study is expected to begin by April 2024.

Veru Inc. reported a net income of $6.3 million, or $0.07 per share, compared to a net loss of $22.2 million, or $0.28 per share for Q3 2022. The company's cash burn was $7.3 million, a reduction of $16.1 million compared to the prior quarter. They also sold ENTADFI® to Blue Water Biotech for $20 million upfront, with potential for up to an additional $80 million from sales milestones.

Veru Inc. reported a decrease in net revenues to $6.6 million from $13.0 million, a decrease in gross profit to $4.1 million from $11.2 million, and a net loss of $38.8 million, or $0.48 per share, compared to a net loss of $14.2 million, or $0.18 per share for the second quarter of fiscal year 2022. The company sold ENTADFI® for $20 million, plus up to an additional potential $80 million from sales milestones and entered into a common stock purchase agreement with Lincoln Park Capital for up to $100 million.

Veru Inc. reported a decrease in net revenues to $2.5 million and a gross profit decrease to $0.7 million for the first quarter of fiscal year 2023. The company is focused on seeking emergency authorization for sabizabulin and advancing clinical studies.

Veru Inc. reported its fiscal 2022 fourth quarter and full year financial results. The company is preparing for commercialization of sabizabulin, while also working to regenerate FC2 product sales.

Veru Inc. reported a 46% decrease in total net revenues, a 49% decrease in gross profit, and a net loss of $22.2 million for the third quarter of fiscal year 2022. The company is progressing with regulatory submissions for sabizabulin as a treatment for COVID-19.

Veru Inc. reported a decrease in total net revenues by 2% to $13.0 million, while US FC2 prescription net revenues climbed 12% to $11.6 million. The company experienced an operating loss of $11.8 million and a net loss of $14.2 million, or $0.18 per share.

Veru Inc. reported a decrease in total net revenues by 3% to $14.1 million. US FC2 prescription net revenues climbed 27% to $11.6 million, and gross profit rose 9% to $11.8 million. The company's operating loss was $5.0 million, and net loss was $6.4 million or $0.08 per diluted share.

Veru Inc. reported a 33% increase in net revenues for the fourth quarter of fiscal year 2021, reaching $15.6 million compared to $11.7 million in the same period of the previous year. The company's gross profit also increased by 29% to $12.3 million. The company is advancing its drug pipeline, particularly in breast and prostate cancer treatments, and is awaiting the PDUFA date for ENTADFI.

Veru Inc. reported a significant increase in net revenues and gross profit for the third quarter of fiscal year 2021. Net revenues increased by 71% to $17.7 million, and gross profit increased by 113% to $13.9 million. The company is focused on advancing its late-stage drug pipeline for oncology and COVID-19.

Veru Inc. reported a 34% increase in net revenues and a 47% increase in gross profit for the fiscal 2021 second quarter, driven by record high quarterly FC2 US prescription net revenues.

Veru Inc. reported a strong fiscal 2021 first quarter, with net revenues increasing by 38% and gross profit rising by 49%. The company is advancing its oncology drug pipeline and anticipates submitting a New Drug Application with the FDA for TADFIN.

Veru Inc. reported a strong Q4 2020, with a 35% increase in net revenues to $11.7 million and a 64% increase in gross profit to $9.6 million. The company's FC2 prescription net revenues climbed 87% to $8.7 million, driving a gross margin of 81%. The company sold its PREBOOST business for $20 million.

Veru Inc. reported an increase in net revenues for the fiscal 2020 third quarter, driven by strong U.S. prescription sales of FC2 and a solid contribution from PREBOOST® / Roman Swipes®, along with lower operating expenses.

Veru Inc. reported a strong fiscal 2020 second quarter with net revenues increasing by 43% and gross profit up by 61%. The growth was primarily driven by substantial growth in prescription sales of FC2. The company also made significant clinical progress in advanced prostate cancer with VERU-111 and initiated a Phase 2 clinical study for VERU-111 as a potential treatment for COVID-19.

Veru Inc. reported a strong fiscal 2020 first quarter with a 66% increase in net revenues and a 57% rise in gross profit, primarily driven by growth in FC2 prescription sales and increased demand for PREBOOST®/Roman® Swipes. The company continues to invest in its prostate and oncology drug pipeline.